Tarsus Announces the Appointment of Elizabeth Yeu, MD, to its Board of Directors

Tarsus Announces the Appointment of Elizabeth Yeu, MD, to its Board of Directors

January 05, 2022

Tarsus Pharmaceuticals announced that Elizabeth Yeu, MD, has been appointed to its Board of Directors. Dr. Yeu will continue to serve as the company’s Chief Medical Advisor.

As part of her board position, she will join the Science and Technology Committee, which provides strategic direction on external and internal innovation and pipeline prospects. Dr. Yeu brings established clinical leadership to the Tarsus Board with over 20 years of diverse eye care experience.

“We are delighted to have Dr. Yeu join our Board of Directors during a pivotal time for the company as we approach the potential commercialization of TP-03, our lead investigational product for the treatment of Demodex blepharitis,” said Bobak Azamian, MD, PhD, President and Chief Executive Officer of Tarsus.

“Dr. Yeu is a prominent and well-respected thought leader and clinician and has a deep understanding of the unmet needs in eye care. I am grateful for her expertise and guidance as we plan for the company’s growth and pipeline expansion.”

Dr. Yeu brings a wealth of eye care experience to the Tarsus Board, having produced hundreds of articles and given several presentations on topics like refractive cataract surgery, anterior segment reconstruction, and external ocular disease management.

In addition to serving as Tarsus' Chief Medical Advisor since August 2020, Dr. Yeu is also a partner and practicing ophthalmologist at Virginia Eye Consultants and Medical Director at Virginia Surgery Center.

She also serves on numerous national medical boards and committees, including as an examiner for the American Board of Ophthalmology and as the Chair of the Cataract Section of Ophthalmic News & Education (ONE) Network for the American Academy of Ophthalmology (AAO).

Dr. Yeu is also an Executive Committee member and the current Secretary for the American Society of Cataract and Refractive Surgery (ASCRS) and, in 2023, she will become the ASCRS President.

“Tarsus has made remarkable progress in advancing TP-03 for the treatment of Demodex blepharitis, and I am honored to have the opportunity to broaden my responsibility by joining the Board of Directors and the Science and Technology Committee,” said Dr. Yeu.

“The company is at the forefront of developing multiple innovative therapeutics that have the potential to make a meaningful difference in many patients’ daily lives, and I am delighted to contribute towards the strategic path of the company.”